Literature DB >> 7693973

Immune escape by human immunodeficiency virus type 1 from neutralizing antibodies: evidence for multiple pathways.

B A Watkins1, M S Reitz, C A Wilson, K Aldrich, A E Davis, M Robert-Guroff.   

Abstract

Sera from many HIV-1-infected individuals contain broadly reactive, specific neutralizing antibodies. Despite their broad reactivity, variant viruses, resistant to neutralization, can be selected in vitro in the presence of such antisera. We have previously shown that neutralization resistance of an escape mutant with an amino acid substitution in the transmembrane protein (A582T) occurs because of alteration of a conformational epitope that is recognized by neutralizing antibodies directed against the CD4 binding site. In this report we demonstrate that immune escape via a single-amino-acid substitution (A281V) within a conserved region of the envelope glycoprotein gp120 confers neutralization resistance against a broadly reactive neutralizing antiserum from a seropositive individual. We show this alteration affects V3 and additional regions unrelated to V3 or the CD4 binding site. Together with previous studies on escape mutants selected in vitro, our findings suggest that immune-selective pressure can arise by multiple pathways.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 7693973      PMCID: PMC238215     

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  42 in total

Review 1.  HIV-1 neutralization directed to epitopes other than linear V3 determinants.

Authors:  K S Steimer; P J Klasse; J A McKeating
Journal:  AIDS       Date:  1991       Impact factor: 4.177

2.  Complete nucleotide sequence of the AIDS virus, HTLV-III.

Authors:  L Ratner; W Haseltine; R Patarca; K J Livak; B Starcich; S F Josephs; E R Doran; J A Rafalski; E A Whitehorn; K Baumeister
Journal:  Nature       Date:  1985 Jan 24-30       Impact factor: 49.962

3.  Genomic diversity of the acquired immune deficiency syndrome virus HTLV-III: different viruses exhibit greatest divergence in their envelope genes.

Authors:  B H Hahn; M A Gonda; G M Shaw; M Popovic; J A Hoxie; R C Gallo; F Wong-Staal
Journal:  Proc Natl Acad Sci U S A       Date:  1985-07       Impact factor: 11.205

4.  Evidence that the structural conformation of envelope gp120 affects human immunodeficiency virus type 1 infectivity, host range, and syncytium-forming ability.

Authors:  L Stamatatos; C Cheng-Mayer
Journal:  J Virol       Date:  1993-09       Impact factor: 5.103

5.  Characterization of conserved human immunodeficiency virus type 1 gp120 neutralization epitopes exposed upon gp120-CD4 binding.

Authors:  M Thali; J P Moore; C Furman; M Charles; D D Ho; J Robinson; J Sodroski
Journal:  J Virol       Date:  1993-07       Impact factor: 5.103

6.  An immune-selected point mutation in the transmembrane protein of human immunodeficiency virus type 1 (HXB2-Env:Ala 582(-->Thr)) decreases viral neutralization by monoclonal antibodies to the CD4-binding site.

Authors:  P J Klasse; J A McKeating; M Schutten; M S Reitz; M Robert-Guroff
Journal:  Virology       Date:  1993-09       Impact factor: 3.616

7.  A molecular clone of HTLV-III with biological activity.

Authors:  A G Fisher; E Collalti; L Ratner; R C Gallo; F Wong-Staal
Journal:  Nature       Date:  1985 Jul 18-24       Impact factor: 49.962

8.  Molecular characterization of human T-cell leukemia (lymphotropic) virus type III in the acquired immune deficiency syndrome.

Authors:  G M Shaw; B H Hahn; S K Arya; J E Groopman; R C Gallo; F Wong-Staal
Journal:  Science       Date:  1984-12-07       Impact factor: 47.728

9.  DNA sequencing with chain-terminating inhibitors.

Authors:  F Sanger; S Nicklen; A R Coulson
Journal:  Proc Natl Acad Sci U S A       Date:  1977-12       Impact factor: 11.205

10.  Frequent detection and isolation of cytopathic retroviruses (HTLV-III) from patients with AIDS and at risk for AIDS.

Authors:  R C Gallo; S Z Salahuddin; M Popovic; G M Shearer; M Kaplan; B F Haynes; T J Palker; R Redfield; J Oleske; B Safai
Journal:  Science       Date:  1984-05-04       Impact factor: 47.728

View more
  21 in total

1.  Evolution of the human immunodeficiency virus type 1 envelope during infection reveals molecular corollaries of specificity for coreceptor utilization and AIDS pathogenesis.

Authors:  Q X Hu; A P Barry; Z X Wang; S M Connolly; S C Peiper; M L Greenberg
Journal:  J Virol       Date:  2000-12       Impact factor: 5.103

2.  Potent human immunodeficiency virus-neutralizing and complement lysis activities of antibodies are not obligatorily linked.

Authors:  Michael Huber; Viktor von Wyl; Christoph G Ammann; Herbert Kuster; Gabriela Stiegler; Hermann Katinger; Rainer Weber; Marek Fischer; Heribert Stoiber; Huldrych F Günthard; Alexandra Trkola
Journal:  J Virol       Date:  2008-01-30       Impact factor: 5.103

3.  Fine mapping of the interaction of neutralizing and nonneutralizing monoclonal antibodies with the CD4 binding site of human immunodeficiency virus type 1 gp120.

Authors:  Ralph Pantophlet; Erica Ollmann Saphire; Pascal Poignard; Paul W H I Parren; Ian A Wilson; Dennis R Burton
Journal:  J Virol       Date:  2003-01       Impact factor: 5.103

4.  Simian immunodeficiency virus engrafted with human immunodeficiency virus type 1 (HIV-1)-specific epitopes: replication, neutralization, and survey of HIV-1-positive plasma.

Authors:  Eloisa Yuste; Hannah B Sanford; Jill Carmody; Jacqueline Bixby; Susan Little; Michael B Zwick; Tom Greenough; Dennis R Burton; Douglas D Richman; Ronald C Desrosiers; Welkin E Johnson
Journal:  J Virol       Date:  2006-03       Impact factor: 5.103

5.  Spontaneous reversion of human immunodeficiency virus type 1 neutralization-resistant variant HXB2thr582: in vitro selection against cytopathicity highlights gp120-gp41 interactive regions.

Authors:  T L Stern; M S Reitz; M Robert-Guroff
Journal:  J Virol       Date:  1995-03       Impact factor: 5.103

6.  A neutralizing antibody-inducing peptide of the V3 domain of feline immunodeficiency virus envelope glycoprotein does not induce protective immunity.

Authors:  S Lombardi; C Garzelli; M Pistello; C Massi; D Matteucci; F Baldinotti; G Cammarota; L da Prato; P Bandecchi; F Tozzini
Journal:  J Virol       Date:  1994-12       Impact factor: 5.103

7.  Increased sensitivity to CD4 binding site-directed neutralization following in vitro propagation on primary lymphocytes of a neutralization-resistant human immunodeficiency virus IIIB strain isolated from an accidentally infected laboratory worker.

Authors:  Tim Beaumont; Esther Quakkelaar; Ad van Nuenen; Ralph Pantophlet; Hanneke Schuitemaker
Journal:  J Virol       Date:  2004-06       Impact factor: 5.103

8.  Enhanced sensitivity to neutralizing antibodies in a variant of equine infectious anemia virus is linked to amino acid substitutions in the surface unit envelope glycoprotein.

Authors:  R F Cook; S L Berger; K E Rushlow; J M McManus; S J Cook; S Harrold; M L Raabe; R C Montelaro; C J Issel
Journal:  J Virol       Date:  1995-03       Impact factor: 5.103

9.  Correlation between env V1/V2 region diversification and neutralizing antibodies during primary infection by simian immunodeficiency virus sm in rhesus macaques.

Authors:  Brian J Rybarczyk; David Montefiori; Philip R Johnson; Ande West; Robert E Johnston; Ronald Swanstrom
Journal:  J Virol       Date:  2004-04       Impact factor: 5.103

10.  Multiple interactions across the surface of the gp120 core structure determine the global neutralization resistance phenotype of human immunodeficiency virus type 1.

Authors:  Peter Bouma; Maria Leavitt; Peng Fei Zhang; Igor A Sidorov; Dimiter S Dimitrov; Gerald V Quinnan
Journal:  J Virol       Date:  2003-07       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.